For the quarter ended June 2025, Bausch Health (BHC Quick QuoteBHC - Free Report) reported revenue of $2.53 billion, up 5.3% over the same period last year. EPS came in at $0.90, compared to $0.89 in the year-ago quarter.

The reported revenue represents a surprise of +2.42% over the Zacks Consensus Estimate of $2.47 billion. With the consensus EPS estimate being $0.97, the EPS surprise was -7.22%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Bausch performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Diversified Products- Dentistry: $25 million versus the three-analyst average estimate of $24.59 million. The reported number represents a year-over-year change of 0%.
• Revenues- Bausch + Lomb- Surgical: $216 million compared to the $220.24 million average estimate based on three analysts. The reported number represents a change of +3.4% year over year.
• Revenues- Diversified Products- Ortho Dermatology: $55 million versus the three-analyst average estimate of $58.84 million. The reported number represents a year-over-year change of -25.7%.
• Revenues- Diversified Products- Neuro: $118 million versus the three-analyst average estimate of $122.87 million. The reported number represents a year-over-year change of -7.8%.
• Revenues- Diversified Products- Generics: $21 million versus $18.15 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -12.5% change.
• Revenues- Salix: $627 million versus the three-analyst average estimate of $588.75 million. The reported number represents a year-over-year change of +12.4%.
• Revenues- International: $278 million versus $279.64 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +0.7% change.
• Revenues- Solta Medical: $128 million compared to the $123.2 million average estimate based on three analysts. The reported number represents a change of +25.5% year over year.
• Revenues- Diversified Products: $219 million compared to the $224.52 million average estimate based on three analysts. The reported number represents a change of -12.8% year over year.
• Revenues- Total Bausch + Lomb revenues: $1.28 billion versus the three-analyst average estimate of $1.25 billion. The reported number represents a year-over-year change of +5.1%.
• Revenues- Total Bausch Health (excl. B+L): $1.25 billion versus the three-analyst average estimate of $1.22 billion. The reported number represents a year-over-year change of +5.5%.
• Revenues- Bausch + Lomb- Ophthalmic Pharmaceuticals: $309 million versus the three-analyst average estimate of $305.73 million. The reported number represents a year-over-year change of -0.3%.

View all Key Company Metrics for Bausch here>>>

Shares of Bausch have returned +0.4% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.